xeloda and metastatic breast cancer

Release time ：Dec-23,2024

Xeloda is a medication frequently employed in the treatment of metastatic breast cancer, functioning by inhibiting the proliferation of tumor cells to achieve therapeutic outcomes. However, Xeloda is not indicated for all metastatic breast cancer patients; its therapeutic efficacy and safety profile must be assessed under the supervision of a physician.

Xeloda's mechanism of action involves the inhibition of thymidine phosphorylase, which halts DNA synthesis and cell division in tumor cells. Side effects such as nausea, vomiting, diarrhea, and hand-foot syndrome may arise during Xeloda treatment. Consequently, patients must adhere to a physician's guidance when using Xeloda and undergo regular blood tests and other necessary evaluations to monitor the drug's efficacy and potential side effects.

For individuals with metastatic breast cancer, seeking timely medical attention and adhering to standardized treatment protocols is crucial. Patients should follow their doctor's recommendations when taking Xeloda or other medications, refraining from adjusting dosages or discontinuing treatment without professional advice. Additionally, maintaining healthy lifestyle practices, including a balanced diet, regular physical activity, and emotional well-being, can significantly contribute to enhancing treatment outcomes and overall quality of life.